According to Future Market Insights research, during the projected period, the global small molecule CMO/CDMO market is expected to grow at a CAGR of 5.2%. The market value is projected to increase from USD 74,998.1 million in 2024 to USD 124,532.4 million by 2034. The small molecule CMO/CDMO market was valued at USD 68,455.5 million at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 5.2% in 2024.

Market Outlook:

Key Market Attributes	Details
Market Size, 2022	USD 68,455.5 Million
Market Size, 2024	USD 74,998.1 Million
Market Size, 2034	USD 124,532.4 Million
Value CAGR (2024 to 2034)	5.2%

Country-wise insights

Country	Value CAGR
United States	4.8%
Germany	3.9%
United Kingdom	3.5%
Japan	5.2%
China	6.5%

Category-wise Insights

Product	Value CAGR
Standard API	4.5%
HPAPI	7.5%

Service	Value CAGR
Process Development	4.1%
Analytical Method Development	4.5%
GMP Manufacturing Service	4.9%
Scale-Up and Tech Transfer	7.4%
Quality Control and Quality Assurance	5.6%
Regulatory Assistance	6.4%
Technology and Innovation	7.9%

Details on Leading Company Size within the Global Market

Company Size	Value CAGR
Large	5.3%
Mid-sized	4.8%
Small	6.0%

Scale of Operation	Value CAGR
Clinical	3.8%
Commercial	5.6%

Competitive Landscape

Particulars	Value CAGR
Global CDMO Market	9.8%
Global CMO/CDMO Market	5.7%
Global Biopharmaceutical Contract Manufacturing Market	10.5%

The Asia-Pacific CDMO Market Report is Segmented by Service Type CMO Segment (Active Pharmaceutical Ingredient (API) Manufacturing [Small Molecule, Large Molecule, High Potency (HPAPI)], Finished Dosage Formulation (FDF) Development and Manufacturing [Solid Dose Formulation (Tablets and Others), Liquid Dose Formulation, and Injectable Dose Formulation], and Secondary Packaging), Research Phase CRO Segment (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), and Country (Asia-Pacific (China, India, Japan, Australia, and Rest of Asia-Pacific)). The Market Size and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

This statistic shows the size of the (pharmaceutical) contract development and manufacturing organizations (CDMOs) market worldwide, projected for the period from 2020 to 2030. By 2030, the global CDMO market is expected to exceed 220 billion U.S. dollars.

The small molecule innovator CDMO market size is projected to be valued at US$ 48.09 billion in 2023 and is expected to rise to US$ 89.43 billion by 2033. The sales of small molecule innovator CDMO are expected to grow at a significant CAGR of 6.4% during the forecast period

Attribute	Details
Small Molecule Innovator CDMO Market Estimated Size (2023)	US$ 48.09 billion
Small Molecule Innovator CDMO Market CAGR (2023 to 2033)	6.4%
Small Molecule Innovator CDMO Market Forecasted Size (2033)	US$ 89.43 billion

Scope of the Report

Attribute	Details
Growth Rate	CAGR of 6.4% from 2023 to 2033
Base Year of Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Billion and Volume in Units and F-CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends and Pricing Analysis
Key Segments Covered	By Therapeutic Area By Product By Stage Type By Customer Type By Region
Regions Covered	North America Latin America Europe East Asia South Asia Middle East & Africa Oceania
Key Countries Profiled	USA Canada Brazil Mexico Germany Italy France United kingdom Spain Russia China Japan India GCC Countries Australia
Key Companies Profiled	Piramal Pharma Solutions; CordenPharma International; Wuxi AppTec; Cambrex Corporation; Recipharm AB; Pantheon (Thermo Fisher Scientific); Lonza; Catalent Inc.; Siegfried Holding AG; Boehringer Ingelheim; Labcorp Drug Development
Customization & Pricing	Available upon Request

The Healthcare Contract Development and Manufacturing Organization Market is Segmented By Services (Contract Development (Small Molecule (Preclinical (Bioanalysis and DMPK Studies, Toxicology Testing, and Other Preclinical Services) Clinical (Phase I, Phase II, Phase III, and Phase IV), Large Molecule (Cell Line development, Process Development (Upstream (Microbial, Mammalian, and Others), and Downstream (MABs, Recombinant Proteins, and Others) and Others) and (Contract Manufacturing (Small Molecule, Large Molecule (MABs, Recombinant Protein, and Others), High Potency API, Finished Dose Formulations (Solid Dose Formulation, Liquid Dose Formulation, and Injectable Dose Formulation), and Medical Devices (Class I, Class II, and Class III)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments.

Global Pharmaceutical CDMO Market size was worth around USD 155.7 billion in 2023 and is grow to USD 291.1 billion by 2032 with a CAGR of roughly 7.20%.

This statistic shows the size of the (pharmaceutical) contract development and manufacturing organizations (CDMOs) market worldwide, projected for the period from 2023 to 2033. By 2033, the global CDMO market is expected to exceed 320 billion U.S. dollars.

Global biologics CDMO market is expected to grow at a CAGR of 15.43% during the forecast period 2023-2032 and attain a value of $80.05 billion by 2032.

The global market for CMO/CDMO is forecasted to attain USD 4,023.9 million by 2025, expanding at 3.1% CAGR to reach USD 5,460.6 million by 2035. In 2024, the revenue of CMO/CDMO was around USD 3,871.9 million.

Metric	Value
Industry Size (2025E)	USD 4,023.9 million
Industry Value (2035F)	USD 5,460.6 million
CAGR (2025 to 2035)	3.1%

Country Wise Analysis

Country	CAGR (2025 to 2035)
USA	1.8%

Country	CAGR (2025 to 2035)
Germany	3.2%

Country	CAGR (2025 to 2035)
China	5.8%

Country	CAGR (2025 to 2035)
India	6.6%

Country	CAGR (2025 to 2035)
Brazil	1.2%

Competitive Outlook

Company Name	Estimated Market Share (%)
Lonza Group	6.6%
Catalent, Inc.	13.4%
WuXi AppTec	6.3%
Samsung Biologics	9.4%
Thermo Fisher Scientific (Patheon)	10.6%
Other Companies (combined)	53.7%

The Biologics CDMO Market Report is Segmented by Type (Mammalian and Non-Mammalian (Microbial)), Product Type (Biologics (Monoclonal, Recombinant Proteins, Antisense and Molecular Therapy, Vaccines, and Other Biologics) and Biosimilars), and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

The Large Molecules Drug Substance CDMO Market Report is Segmented by Service (Contract Manufacturing (Clinical and Commercial), Contract Development (Cell Line Development and Process Development), Source (Mammalian, Microbial, and Other Sources), and End Users (Biotech Companies, Research Institutes, and Other End Users). The Report Offers the Value (in USD) for the Above Segments.

Asia Pacific Pharmaceutical CDMO Market is projected to reach USD 140.03 billion by 2031, growing at a CAGR of 9.9% during the forecast period.

The global inhalation CDMO industry is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from US$ 8,639.1 million in 2024 to US$ 14,863.6 million in 2034.

Attributes	Key Insights
Base Value, 2023	US$ 8,144.2 million
Estimated Global Inhalation CDMO Market Size (2024E)	US$ 8,639.1 million
Forecast Inhalation CDMO Market Value (2034F)	US$ 14,863.6 million
Value-based CAGR (2024 to 2034)	5.7%

Country-wise Insights

Countries	Value CAGR (2024 to 2034)
United States	2.6%
China	10.8%
Japan	4.9%
Germany	2.3%
Spain	3.8%

Category-wise Insights

Segment	Value CAGR (2024 to 2034)
Commercial (Scale of Operation)	6.3%
Formulation Development (Services)	4.5%
API (Product)	6.0%
Medium (Company Size)	3.6%

Scope of the Report

Attribute	Details
Estimated Market Size (2024)	US$ 8,639.1 million
Forecast Market Value (2034)	US$ 14,863.6 million
Anticipated Growth Rate (2024 to 2034)	5.7%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	US$ million for Value
Key Regions Covered	North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, Middle East and Africa
Key Countries Covered	United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia and New Zealand, GCC Countries, South Africa, and Türkiye
Key Market Segments Covered	Service, Product, Company Size, Scale of Operation, and Region
Key Companies Profiled	Recipharm AB AptarGroup, Inc. Hovione Vectura Group Ltd Nemera Kindeva H&T Presspart Sanner GmbH Stevanato Group Medspray ICONOVO AB Lonza Gerresheimer AG Catalent Patheon N.V. (Thermo Fisher Scientific, Inc.) Lubrizol Life Science Enteris BioPharma Cambrex Corporation INKE Piramal Pharma Limited Lupin
Report Coverage	Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities, Trends Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

The size and share of the market is categorized based on Type (Primary Packaging, Secondary Packaging) and Application (Pharmaceutical Industry, Bio-Pharmaceutical) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Biologics CDMO Market is projected to grow at 14.8% CAGR, reaching $42.33 Billion by 2029. Where is the industry heading next? Get the sample report now!

The Small Molecule Innovator CDMO Market is projected to grow at 8.8% CAGR, reaching $85.28 Billion by 2029. Where is the industry heading next? Get the sample report now!

The Report Covers Active Pharmaceutical Ingredients CDMO Market Trends and Companies. It is Segmented by Molecule Type (Small Molecule and Large Molecule), Synthesis (Biotech and Synthetic), Drug Type (Innovative and Generics), Workflow (Clinical and Commercial), Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD) for the Above Segments.

Global Peptide and Oligonucleotide CDMO Market size & share estimated to surpass USD 4,646.57 million by 2032, to grow at a CAGR of 10.6% during the forecast period.

The global nucleic acid therapeutics CDMO market is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033.

The immunoassay CDMO market is estimated to reach USD 11,274.0 million in 2025. It is estimated that revenue will increase at a CAGR of 8.9% between 2025 and 2035. The market is anticipated to reach USD 26,528.5 million by 2035.

Metric	Value
Industry Size (2025E)	USD 11,274.0 million
Industry Value (2035F)	USD 26,528.5 million
CAGR (2025 to 2035)	8.9%

Country-wise Insights

Countries	Value CAGR (2025 to 2035)
United States	4.7%
Canada	3.1%
United Kingdom	3.7%
Germany	2.8%
India	5.8%
China	6.2%
South Korea	5.3%

Category-wise Insights

By Services	Value Share (2025)
Manufacturing and Production	52.8%

End User	Value Share (2025)
Diagnostic Companies	48.2%